Criteria for Anti-Amyloid Therapy and New Insights on Alzheimer's Biomarkers

This chapter outlines the eligibility requirements for dementia patients considering anti-amyloid therapy, emphasizing the necessity of detecting amyloid plaques through PET scans. It also explores the implications of late diagnoses and introduces emerging research on an Alzheimer's biomarker in newborns, before transitioning to a discussion on SSRIs and their safety during pregnancy.